Physician profile
Nathan Chertack
NPI 1568968600
$901.25
in general payments reported to CMS, 2019-2025
16 companies · $489 in 2025
The $489 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $131 · 2024: $281 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $288.55 | 2024-2025 | Gemtesa, Orgovyx |
| Antares Pharma, INC. | $100.47 | 2025 | Xyosted |
| Boston Scientific Corporation | $92.73 | 2023 | Lithovue |
| Janssen Biotech, INC. | $54.13 | 2024-2025 | Erleada |
| Astellas Pharma US INC | $51.06 | 2024-2025 | Xtandi |
| Solventum Corporation | $43.82 | 2024 | V.A.C. Veraflo, Activ.A.C., Prevena |
| Pfizer INC. | $40.17 | 2025 | |
| Teleflex LLC | $38.66 | 2023 | Urolift |
| C. R. Bard, INC. & Subsidiaries | $35.48 | 2025 | Aptra |
| Ferring Pharmaceuticals INC. | $29.07 | 2025 | Adstiladrin |
| Astrazeneca Pharmaceuticals LP | $27.97 | 2025 | Lynparza |
| Endo USA, INC. | $23.11 | 2024 | Aveed, Xiaflex |
| Merck Sharp & Dohme LLC | $22.82 | 2025 | Keytruda |
| Convatec INC. | $20.16 | 2024 | |
| Abbvie INC. | $18.66 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Provepharm INC. | $14.39 | 2025 | Bludigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Chertack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.